Participants 241 289 3
children with acute lymphoblastic leukemia (ALL)
Participants 577 860 6
171 children with standard-risk ALL, age 1 to 9.99 years at diagnosis, previously randomly assigned to IT methotrexate (n = 82) or to triple IT therapy (n = 89) on CCG 1952, underwent neurocognitive evaluation by a licensed psychologist at a mean of 5.9 years after random assignment
Participants 870 907 3
Patients who received IT methotrexate
